PT1117403E - Antagonistas de mglurs para o tratamento da dor e ansiedade - Google Patents

Antagonistas de mglurs para o tratamento da dor e ansiedade

Info

Publication number
PT1117403E
PT1117403E PT99948905T PT99948905T PT1117403E PT 1117403 E PT1117403 E PT 1117403E PT 99948905 T PT99948905 T PT 99948905T PT 99948905 T PT99948905 T PT 99948905T PT 1117403 E PT1117403 E PT 1117403E
Authority
PT
Portugal
Prior art keywords
pain
treatment
anxiety
antagonists
mglurs
Prior art date
Application number
PT99948905T
Other languages
English (en)
Inventor
Hans Allgeier
Nicholas David Cosford
Peter Josef Flor
Fabrizio Gasparini
Conrad Gentsch
Stephen D Hess
Edwin Carl Johnson
Rainer Kuhn
Mark Tricklebank
Laszlo Urban
Mark Andrew Varney
Gonul Veli Elebi
Katharine Walker
Original Assignee
Sibia Neurosciences Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26314451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1117403(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9821503.1A external-priority patent/GB9821503D0/en
Application filed by Sibia Neurosciences Inc, Novartis Ag filed Critical Sibia Neurosciences Inc
Publication of PT1117403E publication Critical patent/PT1117403E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PT99948905T 1998-10-02 1999-09-30 Antagonistas de mglurs para o tratamento da dor e ansiedade PT1117403E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9821503.1A GB9821503D0 (en) 1998-10-02 1998-10-02 Organic compounds
US22081398A 1998-12-23 1998-12-23

Publications (1)

Publication Number Publication Date
PT1117403E true PT1117403E (pt) 2004-04-30

Family

ID=26314451

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99948905T PT1117403E (pt) 1998-10-02 1999-09-30 Antagonistas de mglurs para o tratamento da dor e ansiedade

Country Status (21)

Country Link
EP (1) EP1117403B1 (pt)
JP (1) JP2002526408A (pt)
KR (1) KR20010088832A (pt)
CN (1) CN1187048C (pt)
AT (1) ATE255894T1 (pt)
AU (1) AU765644B2 (pt)
BR (1) BR9914215A (pt)
CA (1) CA2345137A1 (pt)
DE (1) DE69913548T2 (pt)
DK (1) DK1117403T3 (pt)
ES (1) ES2213389T3 (pt)
HU (1) HUP0200553A3 (pt)
ID (1) ID29095A (pt)
IL (2) IL142047A0 (pt)
NO (1) NO20011440L (pt)
NZ (1) NZ510743A (pt)
PL (1) PL202906B1 (pt)
PT (1) PT1117403E (pt)
RU (1) RU2232017C2 (pt)
SK (1) SK4382001A3 (pt)
WO (1) WO2000020001A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
CN1260226C (zh) 2000-12-22 2006-06-21 弗·哈夫曼-拉罗切有限公司 用作mGluR1拮抗剂的四氢－(苯并或噻吩并)－氮杂䓬－吡嗪和三嗪衍生物
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
SE0303419D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 11
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
FR2883180B1 (fr) * 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
AU2007325836B2 (en) 2006-11-22 2011-07-21 Clinical Research Associates, Llc Methods of treating mental retardation, Down's syndrome, fragile X syndrome and autism
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8586581B2 (en) * 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US20120295942A1 (en) 2010-02-01 2012-11-22 Nicholas James Devereux Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
WO2011150380A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2557183A1 (de) 2011-08-12 2013-02-13 Siemens Aktiengesellschaft Verfahren zum Betrieb einer Konti-Glühe für die Verarbeitung eines Walzguts
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
UA120309C2 (uk) 2015-06-03 2019-11-11 Ф. Хоффманн-Ля Рош Аг Етинільні похідні
AU2018310881C1 (en) 2017-07-31 2021-12-16 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
EP3459939A1 (en) 2017-09-26 2019-03-27 Pragma Therapeutics Novel heterocyclic compounds as modulators of mglur7

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives

Also Published As

Publication number Publication date
IL142047A0 (en) 2002-03-10
EP1117403B1 (en) 2003-12-10
DE69913548T2 (de) 2004-09-23
NZ510743A (en) 2003-10-31
JP2002526408A (ja) 2002-08-20
IL142047A (en) 2007-09-20
EP1117403A1 (en) 2001-07-25
CA2345137A1 (en) 2000-04-13
CN1187048C (zh) 2005-02-02
DE69913548D1 (de) 2004-01-22
KR20010088832A (ko) 2001-09-28
RU2232017C2 (ru) 2004-07-10
WO2000020001A1 (en) 2000-04-13
CN1321087A (zh) 2001-11-07
PL346876A1 (en) 2002-03-11
AU6198499A (en) 2000-04-26
SK4382001A3 (en) 2001-08-06
PL202906B1 (pl) 2009-08-31
HUP0200553A2 (hu) 2002-07-29
NO20011440L (no) 2001-05-15
ID29095A (id) 2001-07-26
ATE255894T1 (de) 2003-12-15
NO20011440D0 (no) 2001-03-21
HUP0200553A3 (en) 2002-11-28
AU765644B2 (en) 2003-09-25
BR9914215A (pt) 2001-07-03
ES2213389T3 (es) 2004-08-16
DK1117403T3 (da) 2004-04-13

Similar Documents

Publication Publication Date Title
PT1117403E (pt) Antagonistas de mglurs para o tratamento da dor e ansiedade
ATE322258T1 (de) Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren
ATE263563T1 (de) Mittel gegen juckreiz
ATE407676T1 (de) Topoisomerasehemmern zur behandlung von chirurgischen verklebungen
DE60233040D1 (de) Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese
SE0203752D0 (sv) New compounds
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
DE60108080D1 (de) Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen
DE60109589D1 (de) Pharmazeutische zusammensetzung zur behandlung von akutem schmerz, chronischem schmerz und/oder neuropathischem schmerz und migräne
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE323661T1 (de) Behandlung von mineralischen stoffen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
EE200300559A (et) Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks
PT1257271E (pt) Utilizacao de pramipexole para o tratamento da dependencia de tabaco/nicotina
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20004419D0 (no) Ny anvendelse
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
NO20024776L (no) Hydroksyfenyl-piperazinyl-metyl-benzamid derivater til behandling av smerte
NO20024777D0 (no) Kinolinyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
TR200402230T4 (tr) O-ikameli 6-metil-tramadol-türevleri
DK1000046T3 (da) Piperazinderivater, der er aktive på den nedre urinvejskanal